Investment
Features
FeesSafety
Academy
More
Pluang+

Compare American Homes 4 Rent Class A (AMH) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

American Homes 4 Rent Class ATrade
Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

American Homes 4 Rent Class A vs Neurocrine Biosciences Inc — how do they compare? American Homes 4 Rent Class A trades at $33.61 (market cap $11.97B), while Neurocrine Biosciences Inc trades at $173.61 (market cap $17.82B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and American Homes 4 Rent Class A pays a 3.97% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.

AMHNBIX
Market Cap
$11.97B$17.82B
Sector
Real EstateHealth
52-Week High
$36.74$180.55
52-Week Low
$27.38$123.10
Enterprise Value
$17.05B$16.91B
Dividend Yield
3.97%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

American Homes 4 Rent Class A

AMH (American Homes 4 Rent) trades at $33.27, up 1.0% with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The company maintains robust fundamentals with 24.48% net income margin and $1.85B revenue in 2025, supported by 95% occupancy rates in the single-family rental market. Recent dividend declaration of $0.33 per share and positive analyst sentiment with 58% buy ratings reinforce strength.

Outlook remains positive given consistent operational performance and strategic focus on Sunbelt and Midwest markets. Key risks include high debt levels at $5.01B and sensitivity to interest rate changes. With consensus price target of $35.68 offering 7.2% upside, the stock presents a compelling opportunity for income and growth investors despite macroeconomic headwinds.

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $177.11, down 1.91% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows a bullish technical signal with moving averages supporting upward trends, while RSI levels indicate potential overbought conditions. Recent news highlights strong sales growth from Ingrezza and pipeline advancements, including the Soleno acquisition, reinforcing long-term growth prospects in neuroscience.

Outlook remains positive with a consensus price target of $194, offering ~9.5% upside. Key opportunities include expanding product portfolio and blockbuster drug performance, while risks involve pipeline execution and market volatility. The stock's high valuation multiples require sustained growth to justify current levels, but analyst sentiment is overwhelmingly bullish with 86% buy ratings.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About American Homes 4 Rent Class A

American Homes 4 Rent is a real estate investment trust primarily focused on acquiring, operating, and leasing single-family homes as rental properties throughout the United States. The company's real estate portfolio is largely comprised of single-family properties in urban markets in the Southern and Midwestern regions of the U.S. American Homes 4 Rent's land holdings also represent a sizable percentage of its total assets in terms of value. The company derives the vast majority of its income in the form of rental revenue from single-family properties through short-term or annual leases. The firm's largest geographical markets include Dallas, Texas

Read more on AMH

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX